Swedish Orphan Biovitrum AB (B6E)

Overview

Swedish Orphan Biovitrum AB (publ), commonly known as Sobi, stands as a prominent biotechnology entity dedicated to the research, development, manufacture, and sale of pharmaceuticals. With its inception in 1939 and headquarters situated in Solna, Sweden, Sobi has carved a niche for itself, particularly focusing on the therapeutic areas of haematology, immunology, and specialty care. Its geographical footprint spans across Europe, North America, the Middle East, Asia, and Australia, underlining its global presence and commitment to addressing rare diseases with innovative solutions. The company also prides itself on strategic collaborations with other industry leaders like Apellis Pharmaceuticals Inc., enhancing its capabilities to tackle complex medical conditions such as paroxysmal nocturnal hemoglobinuria.

Products and Services

Alprolix: A treatment specifically designed for haemophilia B, offering patients a contemporary therapeutic option.

Aspaveli®/Empaveli: Targets the treatment of adult patients suffering from paroxysmal nocturnal haemoglobinuria, providing a vital option for managing this rare and life-threatening blood disorder.

Doptelet: An innovative solution for patients dealing with thrombocytopenia, focusing on improving platelet counts and reducing the risks associated with low platelet levels.

Elocta: A formulary cornerstone for the treatment of haemophilia A, aiming to improve the quality of life for patients by offering enhanced bleeding protection.

Gamifant: Specifically developed for hemophagocytic lymphohistiocytosis (HLH), offering a critical treatment pathway for this aggressive and life-threatening immune disorder.

Zynlonta: Aimed at treating an aggressive malignant disease, showcasing Sobi’s commitment to cancer therapy and patient care.

Kineret: A versatile treatment option for cryopyrin associated periodic syndrome, rheumatoid arthritis, and Still's disease, demonstrating Sobi’s excellence in immunological therapies.

Orfadin: Designed to treat hereditary tyrosinaemia type-1, this product underscores Sobi’s dedication to addressing rare genetic disorders.

Synagis: Provides a preventative treatment for serious lower respiratory tract infection in infants, a critical care area for paediatric health.

Other Products: The portfolio is further enriched with treatments such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra, covering various therapeutic areas and underscoring the company’s diversified approach to pharmaceuticals.

In addition to these proprietary products, Sobi is involved in the development of drug substances such as ReFacto AF/Xyntha for Pfizer, BIVV001 for haemophilia A, and Nirsevimab for the respiratory syncytial virus, reflecting its active role in partnering and co-developing treatments that address significant unmet medical needs.